On March 18, 2024, Gilead Sciences, Inc announced that it has received a shareholder proposal from John Chevedden, asking the Board of Directors to adopt a policy requiring the 5 named executive officers (NEOs) to retain a significant percentage of stock acquired through equity pay programs until reaching normal retirement age and to report to shareholders regarding the policy in the Company?s next annual meeting proxy. For the purpose of this policy, normal retirement age would be an age of at least 60 and be determined by the Company executive pay committee. Shareholders recommend a share retention percentage requirement of 25% of net after-tax shares.

In addition, the Company urged the shareholders to vote against the shareholder proposal at its annual general meeting of shareholders scheduled to be held on May 8, 2024.